DayTwo’s individualized nutrition profile predicts how a person will respond to different foods and food combinations based on their unique gut microbe composition and other clinical parameters.
DayTwo, the microbiome human discovery platform that offers a glycemic control solution for people with type 2 diabetes, announced $31 Million in Series B financing. DayTwo will use the funding to accelerate go-to-market initiatives in the United States where the company partners with payers, prov... (more)
